[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100626928":3},{"organization":4,"outcomesModule":7,"designInfo":28,"detailedDescription":35,"studyPopulation":11,"armGroups":36,"interventions":51,"overallOfficials":69,"centralContacts":74,"locations":80,"responsibleParty":95,"collaborators":11,"id":97,"slug":11,"hasResults":98,"nctId":99,"briefTitle":100,"officialTitle":101,"acronym":11,"eligibilityCriteria":102,"healthyVolunteers":98,"sex":103,"minAge":104,"maxAge":11,"enrollmentInfo":105,"targetDuration":11,"studyType":108,"phases":109,"briefSummary":100,"conditions":111,"keywords":113,"overallStatus":82,"whyStopped":11,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":119,"completionDateStruct":121,"leadSponsor":123,"locationsCount":124},{"fullName":5,"class":6},"JW Pharmaceutical","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":11},[9],{"measure":10,"description":11,"timeFrame":12},"Mean change in Mean Amplitude of Glycemic Excursion (MAGE) from baseline to week 12",null,"Baseline to week 12",[14,16,18,20,22,25],{"measure":15,"description":11,"timeFrame":12},"Change in the percentage of time spent within the target glucose range (70-180 mg\u002FdL)",{"measure":17,"description":11,"timeFrame":12},"Change from baseline in mean blood glucose at 12 weeks",{"measure":19,"description":11,"timeFrame":12},"Change from baseline in HbA1c at 12 weeks",{"measure":21,"description":11,"timeFrame":12},"Change from baseline in FPG at 12 weeks",{"measure":23,"description":24,"timeFrame":12},"Change from baseline in HOMA-β at 12 weeks","HOMA- β: 20\\*fasting insulin\u002F\\[(fasting plasma glucose\\*0.0555)-3.5\\]",{"measure":26,"description":27,"timeFrame":12},"Change from baseline in HOMA-IR at 12 weeks","HOMA-IR: fasting insulin\\*(fasting glucose\\*0.0555)\u002F22.5",{"allocation":29,"interventionModel":30,"interventionModelDescription":31,"primaryPurpose":32,"observationalModel":11,"timePerspective":11,"maskingInfo":33},"RANDOMIZED","PARALLEL","randomized, open-label, active-controlled, parallel, phase IV","TREATMENT",{"masking":34,"maskingDescription":11,"whoMasked":11},"NONE","A multicenter study to evaluate efficacy and safety",[37,44],{"label":38,"type":39,"description":40,"interventionNames":41},"Experimental","EXPERIMENTAL","Empagliflozin\u002FMetformin + Anagliptin",[42,43],"Drug: Empagliflozin\u002FMetformin","Drug: Anagliptin",{"label":45,"type":46,"description":47,"interventionNames":48},"Active Comparator","ACTIVE_COMPARATOR","Metformin + Empagliflozin\u002FLinagliptin",[49,50],"Drug: Metformin","Drug: Empagliflozin\u002FLinagliptin",[52,57,61,65],{"type":53,"name":54,"description":55,"armGroupLabels":56,"otherNames":11},"DRUG","Empagliflozin\u002FMetformin","5\u002F500 mg, 5\u002F1000 mg (based on prior Metformin dose), for 12 weeks (PO, BID)",[38],{"type":53,"name":58,"description":59,"armGroupLabels":60,"otherNames":11},"Anagliptin","100 mg, for 12 weeks (PO, BID)",[38],{"type":53,"name":62,"description":63,"armGroupLabels":64,"otherNames":11},"Metformin","500 mg, 1000 mg (based on prior Metformin dose), for 12 weeks (PO, BID)",[45],{"type":53,"name":66,"description":67,"armGroupLabels":68,"otherNames":11},"Empagliflozin\u002FLinagliptin","10\u002F5 mg, for 12 weeks (PO, QD)",[45],[70],{"name":71,"affiliation":72,"role":73},"Sung Rae Kim","The Catholic University of Korea, Bucheon St. Mary's Hospital, Principal Investigator","PRINCIPAL_INVESTIGATOR",[75],{"name":76,"role":77,"phone":78,"phoneExt":11,"email":79},"Saemi Kang","CONTACT","82-2-840-6902","kangsm@jwhealthcare.com",[81],{"facility":72,"status":82,"city":83,"state":11,"zip":11,"country":84,"countryCode":11,"cosmosGeoPoint":85,"geoPoint":90,"contacts":91},"RECRUITING","Seoul","South Korea",{"type":86,"coordinates":87},"Point",[88,89],126.9784,37.566,{"lat":89,"lon":88},[92],{"name":71,"role":77,"phone":93,"phoneExt":11,"email":94},"82-32-340-7013","kimsungrae@catholic.ac.kr",{"type":96,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100626928",false,"NCT07442006","Glycemic Variability of Combination Therapies in T2DM","A Multicenter Study to Evaluate Efficacy and Safety","Inclusion Criteria:\n\n* Inadequate glycemic control despite treatment with Metformin (≥ 1,000mg\u002Fday) and SGLT-2 inhibitor.\n\nExclusion Criteria:\n\n* History of acute or chronic metabolic acidosis\n* Moderate to severe renal impairment (eGFR \\\u003C 45 mL\u002Fmin\u002F1.73m²)\n* Severe hepatic impairment\n* History of heart failure (NYHA Class III\u002FIV)","ALL","19 Years",{"count":106,"type":107},178,"ESTIMATED","INTERVENTIONAL",[110],"PHASE4",[112],"Type 2 Diabetes Mellitus (T2DM)",[114],"Glycemic Variability","2026-02-26",{"date":117,"type":118},"2026-03-02","ACTUAL",{"date":120,"type":118},"2025-10-29",{"date":122,"type":107},"2027-03-31",{"name":5,"class":6},1]